导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.65% | 3018/4773 |
| 近一周 | -1.78% | 3336/5467 |
| 近一月 | -2.56% | 986/5421 |
| 近一季 | -0.88% | 1082/5238 |
| 近半年 | -0.95% | 1828/4931 |
| 近一年 | 0.70% | 2428/4400 |
| 近两年 | 36.06% | 2060/2954 |
| 近三年 | 23.08% | 1357/2253 |
| 成立以来 | 48.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.97% 3988/4961 |
6.81% 2790/5312 |
- - |
- - |
| 2025 | 15.76% 2515/4813 |
-0.54% 2296/3635 |
2.80% 1345/4076 |
10.75% 3245/4524 |
2.24% 1033/4813 |
| 2024 | 17.36% 699/3463 |
3.41% 576/2808 |
-0.24% 717/3014 |
16.49% 1442/3129 |
-2.33% 2044/3463 |
| 2023 | -8.36% 1005/2656 |
0.91% 1674/2280 |
-4.40% 1161/2385 |
1.78% 276/2515 |
-6.67% 1868/2655 |
| 2022 | -16.54% 491/2207 |
-10.88% 447/1919 |
6.46% 696/2016 |
-13.09% 830/2113 |
1.22% 1343/2208 |
| 2021 | -7.54% 1038/1822 |
-2.44% 641/1255 |
0.03% 1116/1330 |
-7.22% 1034/1466 |
2.12% 696/1822 |
| 2020 | 24.19% 637/1250 |
-11.21% 823/1028 |
10.46% 767/1067 |
12.73% 369/1164 |
12.33% 480/1184 |
| 2019 | 37.11% 342/1092 |
22.09% 579/739 |
4.32% 29/788 |
2.12% 320/850 |
5.42% 720/918 |
| 2018 | -16.60% 110/834 |
- - |
-7.31% 154/631 |
6.43% 46/660 |
-11.24% 271/682 |
| 2017 | 27.51% 86/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.60% 144/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 天弘上证50ETF联接A VS. 长安沪深300非周期A(740101) |